Objective. To evaluate the efficacy and safety of orally administered once-daily peficitinib in combination with limited conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with moderate-to-severe rheumatoid arthritis (RA).
, and ABT-494 (JAK-1 selective) (14) are currently in various stages of development.
Peficitinib (ASP015K) is an orally administered once-daily JAK inhibitor in development for the treatment of RA (15) . Peficitinib inhibits JAK-1, JAK-2, JAK-3, and Tyk-2 enzyme activities with 50% inhibition concentration values of 3.9, 5.0, 0.7, and 4.8 nmoles/liter, respectively, and therefore has moderate selectivity for JAK-3 inhibition (15) . The efficacy and safety profile of peficitinib for the treatment of RA has been investigated in 2 other phase II trials. In a 12-week, phase IIb, randomized, double-blind, placebocontrolled study of peficitinib monotherapy (25 mg, 50 mg, 100 mg, and 150 mg) in Japanese patients with moderate-tosevere RA (not required to fail to respond to 1 or more conventional synthetic disease-modifying antirheumatic drugs [csDMARDs]; ClinicalTrials.gov identifier NCT01649999), 50 mg, 100 mg, or 150 mg once-daily doses of peficitinib resulted in statistically significant American College of Rheumatology 20% improvement criteria (ACR20) responses (16) compared with placebo, and had satisfactory tolerability (15) . In a second 12-week, phase IIb, randomized, doubleblind, parallel-group, placebo-controlled, dose-finding (peficitinib 25 mg, 50 mg, 100 mg, and 150 mg), multicenter study, statistically significant improvements in ACR20 response with peficitinib combined with methotrexate (MTX) were only observed in the peficitinib 50 mg group compared with placebo plus MTX (P , 0.05) in patients who had an inadequate response to MTX (NCT01554696) (17) .
Here, we report the findings of a third randomized phase IIb study to evaluate the efficacy, safety, and dose response of orally administered once-daily peficitinib over 12 weeks in patients with moderate-to-severe RA who had an inadequate response or intolerance to csDMARDs.
PATIENTS AND METHODS
Study design. This phase IIb, randomized, doubleblind, parallel-group, placebo-controlled, dose-finding, global, multicenter study of orally administered once-daily peficitinib in patients with moderate-to-severe RA who had an inadequate response or intolerance to csDMARDs (ClinicalTrials.gov identifier NCT01565655) was conducted at 41 sites in 6 countries (the US [20 The trial was conducted over 12 weeks, during which patients were seen at baseline and at weeks 1, 2, 4, 8, and 12. Screening visits were performed up to 4 weeks prior to baseline, and patients who completed the 12-week study were given the option to participate in a long-term, open-label extension study. Patients who did not participate in the extension study were included in a 30-day follow-up.
Patients were randomly assigned in a 1:1:1:1:1 ratio to receive either peficitinib 25 mg, 50 mg, 100 mg, 150 mg or matching placebo once a day for 12 weeks. The investigator, patient, clinical staff, and sponsor were blinded with regard to treatment assignments. Study population. Eligible study participants were patients ages $18 years, who had been diagnosed as having RA according to the ACR 1987 revised criteria (18) $6 months prior to screening and who had an inadequate response or intolerance to a previous csDMARD. Patients were also required to be classified as having class I, II, or III functional status according to the ACR 1991 revised criteria for global functional status in RA (19) and to have active RA as defined by $6 tender/painful joints (tender joint count in 68 joints [TJC68]), $6 swollen joints (swollen joint count in 66 joints [SJC66]), and either a C-reactive protein (CRP) level of $0.8 mg/dl (normal range ,1.0 mg/dl) or an erythrocyte sedimentation rate (ESR) of $28 mm/hour at screening and at baseline.
Patients who had taken any of the following csDMARDs or biologic agents within the following periods prior to the first study drug dose were excluded: MTX, gold, azathioprine, minocycline, or penicillamine (28 days); etanercept (28 days); certolizumab, adalimumab, golimumab, infliximab, or tocilizumab (60 days); rituximab or other CD20 inhibitors, or cyclophosphamide (180 days); leflunomide (60 days; if the patient had undergone a cholestyramine washout, the period was reduced to 30 days prior to day 1 dosing); abatacept (90 days); and anakinra (7 days). Exclusion criteria also included abnormal findings on a chest radiograph within 90 days of screening or at screening, indicative of an acute or chronic infectious process or malignancy, virus vaccination within 30 days prior to the first dose of study drug, hepatitis B/C or HIV, any other autoimmune rheumatic disease other than Sj€ ogren's syndrome, clinically significant infections, and any malignancy except for successfully treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix. Additionally, patients who had tuberculosis (TB) who were not taking guideline antimicrobial therapy were excluded. Patients were not required to undergo a TB test at screening if there was documentation of a negative TB test within 90 days of screening or if they had documentation of previously successfully completed treatment for latent TB per the Centers for Disease Control and Prevention or local guidelines. For subjects who had a previous BCG vaccination, QuantiFeron blood testing was conducted to identify latent TB infection within 90 days of screening. Any positive TB test result was considered positive for the purposes of study entry evaluation.
Concomitant medications. The only permitted concomitant medications for RA were nonsteroidal antiinflammatory drugs, csDMARDs (#400 mg hydroxychloroquine per day, #250 mg chloroquine per day, and #3 gm sulfasalazine per day), and/or oral corticosteroids (#10 mg of prednisone or equivalent per day).
Prohibited concomitant medications were biologic agents approved for the treatment of RA (including, but not limited to, abatacept, tocilizumab, rituximab, etanercept, certolizumab, adalimumab, golimumab, and infliximab); csDMARDs (including MTX, gold, penicillamine, leflunomide, azathioprine, minocycline, and cyclophosphamide), intraarticular or parenteral corticosteroids, .10 mg oral prednisone (or equivalent) per day, treatment with another investigational drug, and medications that are CYP3A substrates with a narrow therapeutic range (including, but not limited to, cyclosporine, sirolimus, tacrolimus, and terfenadine).
Study end points. The primary end point was the percentage of patients who met the ACR20 criteria using the CRP level at week 12. Secondary and other end points included the percentages of patients achieving an ACR50 or ACR70 response at week 12, the change from baseline in Disease Activity Score in 28 joints (DAS28) (20) using the CRP level (DAS28-CRP) at week 12, the percentage of patients achieving a DAS28 using the ESR (DAS28-ESR) of ,2.6, the percentage of patients acheiving a DAS28-CRP of ,2.6, and the change from baseline in Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) at week 12.
Safety and laboratory assessments. Safety was assessed through AE reporting (coded using the Medical Dictionary for Regulatory Activities [MedDRA] version 14.0) (21), vital signs, clinical laboratory evaluations (hematology, chemistry, urinalysis, and fasting lipids profile), 12-lead electrocardiograms, and physical examinations. AE grades were based on National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03.
Sample size determination. The planned sample size for the study was 275 patients. Assuming an ACR20 response of 60% for any peficitinib group and 30% for placebo, 55 patients per treatment group (adjusted for an expected 10% dropout rate) were needed to reach 80% power to detect a difference between any of the peficitinib groups and placebo, using a 2-sided continuitycorrected chi-square test with a significance level of 5%.
Statistical analysis. The full analysis set consisted of all patients who were randomized and received at least 1 dose of peficitinib. This was the primary data set for efficacy analyses. Primary analysis of ACR20/50/70 response rates and the change from baseline in DAS28-CRP at week 12 was based on a logistic regression model with effects for treatment group and geographic region. When all ACR component values were missing, nonresponder imputation was used for the missing ACR responses at week 12. If not all ACR component values were missing at week 12, the last observation carried forward (LOCF) was used to impute missing values and then the ACR response was calculated. In addition, patients who received rescue therapy (defined as patients who initiated any csDMARD medication after day 1 or who received intramuscular or intravenous corticosteroids after day 1) prior to or at week 12 were classified as nonresponders. Additional analyses using normal approximation to the binomial distribution were also conducted.
Analysis of covariance with fixed effects for treatment group, geographic region, and baseline score as a covariate was used on the secondary end point of change from baseline in DAS28-CRP. All DAS28 component values at a time point for any patient receiving rescue therapy prior to or at the time point were set to missing, and missing component values were imputed using the LOCF. A mixed-effects model for repeated measures was used for the analysis of change from baseline in CDAI and SDAI, with the patient as a random effect. Treatment stratified by geographic region was excluded from the model if not significant (P , 0.01). Within-patient variancecovariance was estimated using an unstructured covariance matrix. No adjustments for multiplicity were performed in these analyses. The safety analysis set was defined as all patients who received at least 1 dose of peficitinib.
RESULTS

Patients.
A total of 439 patients were screened for inclusion, of which 289 were randomized and treated Demographic characteristics and baseline disease activity were similar across the study arms (Table 1) .
Efficacy. The primary end point of ACR20 response at week 12 was achieved by 22.0%, 36.8%, 48.3%, 56.3%, and 29.4% of patients in the peficitinib 25 mg, 50 mg, 100 mg, 150 mg, and placebo groups, respectively (Figure 2) . Statistically significant differences in the ACR20 1.6 6 0.6 1.4 6 0.6 1.6 6 0.7 1.4 6 0.7 1.5 6 0.7 DAS28-ESR 6.6 6 0.9 6.6 6 0.9 6.7 6 0.8 6.6 6 0.8 6.7 6 1.0 DAS28-CRP 5.9 6 0.9 5.8 6 1.0 5.9 6 0.9 5.7 6 0.9 5.9 6 1.1 * Except where indicated otherwise, values are the number (%). RA 5 rheumatoid arthritis; MTX 5 methotrexate; SSZ 5 sulfasalazine; SDAI 5 Simplified Disease Activity Index; CDAI 5 Clinical Disease Activity Index; TJC68 5 tender joint count in 68 joints; SJC66 5 swollen joint count in 66 joints; CRP 5 C-reactive protein; ESR 5 erythrocyte sedimentation rate; SGAP 5 subject's global assessment of arthritis pain; VAS 5 visual analog scale; SGA 5 subject's global assessment; PGA 5 physician's global assessment; HAQ DI 5 Health Assessment Questionnaire disability index; DAS28-ESR 5 Disease Activity Score in 28 joints using the erythrocyte sedimentation rate; DAS28-CRP 5 DAS28 using the C-reactive protein level.
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response rate versus placebo were reported for the peficitinib 100 mg (P , 0.05) and 150 mg (P , 0.01) groups at week 12. ACR50 response rates at week 12 were 15.3%, 24.6%, 27.6%, 28.1%, and 9.8% in the peficitinib 25 mg, 50 mg, 100 mg, 150 mg, and placebo groups, respectively. The peficitinib 50 mg (P , 0.05), 100 mg (P , 0.05), and 150 mg (P , 0.01) groups had a significantly greater number of patients achieving ACR50 response rates at week 12 than the placebo group. ACR70 response rates at week 12 were 6.8%, 15.8%, 19.0%, 10.9%, and 7.8% in the peficitinib 25 mg, 50 mg, 100 mg, 150 mg, and placebo groups, respectively. No peficitinib treatment group reached statistical significance for ACR70 response rate versus placebo at week 12.
ACR20 responses by geographic region are shown in Supplementary Figure 1, Overall, ACR20 response rates increased over time ( Figure 3A ). Patients in the peficitinib 100 mg and 150 mg groups achieved a significantly greater ACR20 response rate at week 2 (P , 0.05) compared with placebo, which was maintained to week 12. Throughout the 12-week study, least squares mean (LSM) DAS28-ESR and DAS28-CRP levels decreased from baseline in all study arms ( Figures 3B and  C) . Patients in the peficitinib 100 mg and 150 mg groups achieved a statistically significant decrease in both LSM DAS28-ESR and DAS28-CRP from baseline at week 4, which was maintained to week 12.
Statistically significant differences in LSM SDAI and CDAI at week 12 were observed in the peficitinib 50 mg (P , 0.05), 100 mg (P , 0.001), and 150 mg (P , 0.001) groups versus the placebo group (Table 2) . There were no statistically significant differences in LSM Health Assessment Questionnaire (HAQ) disability index (DI) at week 12 between any peficitinib group and placebo. The mean TJC68 and SJC66 decreased further from baseline in the peficitinib groups compared with placebo, and the decreases were dose dependent.
A significantly greater percentage of patients in the peficitinib 100 mg and 150 mg groups achieved a DAS28-ESR of ,2.6 at week 12 compared with placebo (P , 0.05).
No peficitinib group had a significantly greater percentage of patients achieving a DAS28-CRP of ,2.6 at week 12 compared with placebo.
Safety. Adverse events. A total of 121 patients (42%) reported AEs (Table 3) The majority of AEs (88%) were mild or moderate in severity, with a total of 15 serious AEs experienced by 12 patients, and no deaths were reported. The serious AEs Figure 2 . Percentages of patients in each treatment group achieving a response according to the American College of Rheumatology criteria for 20% improvement (ACR20), 50% improvement, and 70% improvement at week 12. * 5 P , 0.05; ** 5 P , 0.01, versus placebo.
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GENOVESE ET AL Figure 3 . Responses over time in each treatment group. A, American College of Rheumatology criteria for 20% improvement (ACR20) response rates. B, Least squares mean (LSM) change from baseline in the Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-ESR). C, LSM change from baseline in the DAS28 using the C-reactive protein level (DAS28-CRP). * 5 P , 0.05; ** 5 P , 0.01; *** 5 P , 0.001, versus placebo. * DAS28-ESR 5 Disease Activity Score in 28 joints using the erythrocyte sedimentation rate; DAS28-CRP 5 DAS28 using the C-reactive protein level; SDAI 5 Simplified Disease Activity Index; LSM 5 least squares mean; 95% CI 5 95% confidence interval; TJC68 5 tender joint count in 68 joints; SJC66 5 swollen joint count in 66 joints; HAQ DI 5 Health Assessment Questionnaire disability index.
† P , 0.05 versus placebo. ‡ P , 0.001 versus placebo. § P values are for comparison of medians between each peficitinib group and placebo based on the Wilcoxon rank sum test stratified by geographic region. ¶ P , 0.01 versus placebo. Absolute neutrophil count, cells/ml ,500
were myocardial ischemia and joint dislocation in the placebo group; RA and limb abscess in the peficitinib 25 mg group; asthma, hemoptysis, and atrial fibrillation in the peficitinib 50 mg group; synovial cyst, humerus fracture, electrocardiogram abnormality and 2 incidents of transient ischemic attack in the peficitinib 100 mg group; and musculoskeletal chest pain, pleuritic pain, and myocardial infarction in the peficitinib 150 mg group. There was 1 case (,1%) of herpes zoster in the placebo group that was not disseminated, and 1 serious infection (limb abscess) in the peficitinib 25 mg group. A total of 9 patients discontinued treatment due to an AE (4 in the peficitinib 25 mg group, 2 in the peficitinib 50 mg group, 1 in the peficitinib 100 mg group, and 2 in the peficitinib 150 mg group). Adverse events that led to discontinuation were dyspepsia (in the peficitinib 100 mg and 150 mg groups; n 5 2), abdominal hernia (in the peficitinib 50 mg group; n 5 1), nausea (in the peficitinib 150 mg group; n 5 1), vomiting (in the peficitinib 100 mg group; n 5 1), hidradenitis (in the peficitinib 25 mg group; n 5 1), skin lesion (in the peficitinib 25 mg group; n 5 1), myocardial infarction (in the peficitinib 150 mg group; n 5 1), limb abscess (in the peficitinib 25 mg group; n 5 1), contusion (in the peficitinib 25 mg group; n 5 1), and RA (in the peficitinib 50 mg group; n 5 1).
Laboratory values. Decreases in the mean absolute neutrophil count from baseline at week 12 were observed in the peficitinib 50 mg, 100 mg, and 150 mg groups. There were no shifts from baseline to any prespecified ranges for absolute neutrophil count or incidences of grade 2 or higher neutropenia at week 12. Decreases in mean absolute lymphocyte count at week 12 were reported in the peficitinib 25 mg and 50 mg groups compared with placebo, and there were no shifts from baseline to any prespecified ranges for absolute lymphocyte count or incidences of grade 2 or higher lymphopenia at week 12. There was a dose-dependent decrease in mean platelet count (no patients shifted from baseline to any prespecified ranges for platelet count at week 12), and treatment with peficitinib was associated with a decreased white blood cell (WBC) count, with no decreases of grade 2 or higher in platelet or WBC count at week 12.
At week 12, the mean alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels remained stable in the placebo and peficitinib 25 mg, 50 mg, and 100 mg groups, but were increased from baseline in the peficitinib 150 mg group. Furthermore, ALT levels in 1 patient in the peficitinib 25 mg group (1.7%) and in 2 patients in the peficitinib 150 mg group (3.1%) shifted from baseline to the prespecified range of .2 times the upper limit of normal (ULN) to #3 times the ULN at week 12. There were no shifts to any prespecified ranges for AST, and there were no incidences of grade 2 or higher increases in ALT or AST levels at week 12.
There were 2 grade 3 or higher increases in creatine phosphokinase (CPK) level throughout the study, 1 each in the peficitinib 100 mg and 150 mg groups. Neither patient had received concomitant statins. The increase in CPK level did not resolve in either patient, but both patients continued until the end of the study. CPK levels in 4 patients (1 in the peficitinib 25 mg group, 2 in the peficitinib 100 mg group, and 1 in the peficitinib 150 mg group) shifted from baseline to the prespecified range of .2 times the ULN to #5 times the ULN at week 12. There were 2 grade 2 or higher CPK elevations at week 12 in the peficitinib 100 mg group. Dose-dependent increases in creatinine were observed across the peficitinib groups. In 1 patient in the peficitinib 50 mg group, the creatinine level shifted from baseline to the prespecified range of .1.5 times baseline to #3.0 times baseline at week 12. There were no grade 2 or higher increases in creatinine at week 12.
The mean change from baseline in high-density lipoprotein (HDL) level was dose dependent, and the change in triglyceride level varied among all groups of patients and was not dose dependent. However, there were 4 incidents of hypertriglyceridemia higher than grade 3 (2 each in the peficitinib 25 mg and 100 mg groups, 3 of which were considered drug related). In a total of 22 patients (1 in the placebo group, 3 in the peficitinib 25 mg group, 6 in the peficitinib 50 mg, 8 in the peficitinib 100 mg group, and 4 in the peficitinib 150 mg group), lowdensity lipoprotein (LDL) level shifted from baseline to .160 mg/dl at week 12. Overall, in 84 patients (14 in the placebo group, 11 in the peficitinib 25 mg group, 20 in the peficitinib 50 mg group, 18 in the peficitinib 100 mg group, and 21 in the peficitinib 150 mg group) the triglyceride level shifted from baseline to .1.68 mmoles/liter at week 12, and in 30 patients (9 in the placebo group, 7 in the peficitinib 25 mg group, 5 in the peficitinib 50 mg group, 5 in the peficitinib 100 mg group, and 4 in the peficitinib 150 mg group) the HDL level shifted from baseline to ,1.06 mmoles/liter at week 12. Lipid ratios (HDL:LDL and HDL:total cholesterol) remained stable in all treatment groups throughout the 12-week study.
DISCUSSION
Patients with RA who had long-term refractory disease and inadequate responses to previous treatment with multiple DMARDs, including biologics, who were treated with peficitinib in combination with limited csDMARDs demonstrated ACR20 dose-dependent response rates at week 12. The peficitinib 100 mg and 150 mg groups showed a statistically significant difference compared with placebo in ACR20 response (starting at week 2 and continuing throughout the study), ACR50 response, and in change from baseline DAS28-CRP. The peficitinib 25 mg and 50 mg groups did not show a statistically significant difference in the percentage of patients achieving an ACR20 response compared with placebo. When ACR20 responses were stratified by geographic region, differences were seen between regions across treatment arms; however, it is difficult to draw any definitive conclusions due to low patient numbers.
In assessment of higher hurdle end points, such as ACR70 response and DAS28-ESR remission at week 12, there was a statistically significant difference in DAS28-ESR remission (but not ACR70 response) with higher doses of peficitinib (100 mg and 150 mg) compared with placebo; however, overall, the proportion of patients achieving these end points with peficitinib was relatively low. Similarly, although there appeared to be a trend toward a dosedependent improvement in HAQ DI with peficitinib compared with placebo, these differences were small and were not statistically significant. Taking into consideration the small number of patients, limited study duration, and that this study involved a heterogeneous patient group with prior exposure to DMARDs and biologic DMARDs, it is difficult to make conclusions regarding these responses.
Treatment with orally administered once-daily peficitinib in combination with limited csDMARDs demonstrated satisfactory tolerability, with an overall incidence of AEs similar to that in the placebo group. Safety evaluation found no dose-related increases in any AEs during this study, and there were no new safety signals compared with other peficitinib phase II trials (15, 17) . However, the total number 940 GENOVESE ET AL of AEs of any grade were lower than anticipated based on data from previous trials with peficitinib (17) and other JAK inhibitors (2) (3) (4) (5) (6) (7) (8) . Dose-dependent decreases in absolute neutrophil count, platelet count, and WBCs, and dose-dependent increases in CPK, HDL, and creatinine levels were seen. Lipid ratios remained stable throughout this study. This study was limited by its short duration and small patient population, consistent with phase II studies. Further challenges to the interpretation of treatment responses in this study included the global design with a varied patient population, the low number of patients from Latin America, and the inclusion of patients who had previously received biologic agents and were not required to have had an inadequate response or intolerance to a biologic agent. Additionally, the permitted use of hydroxychloroquine, chloroquine, and sulfasalazine may be seen as a limitation because it prevented this study from being a true peficitinib monotherapy study; however, because this was a placebo-controlled study, health authorities requested that patients be permitted csDMARD use. Thus, although this was not a monotherapy study, the design permitted assessment of the safety and efficacy of peficitinib in the setting of no background MTX use.
In addition to other inclusion/exclusion criteria, patients were required to have either an elevated CRP or an elevated ESR to enter the trial. Differences in responses were observed between patients who entered the study with an elevated CRP level and those who entered with an elevated ESR (Table 1) . For patients who qualified via an elevated CRP level, a trend was observed toward higher response rates, particularly in the peficitinib 150 mg group, compared with patients who qualified by an elevated ESR. Responses to placebo were also higher in patients who entered with an elevated ESR; this latter group comprised 50% of the enrolled patients. Patients qualifying based on ESR, which is measured locally rather than at a central laboratory, might have been subject to less rigorous laboratory standards and may have influenced the study results.
To fully assess the efficacy and safety of this novel JAK inhibitor, longer-term and larger-scale phase III studies of peficitinib 100 mg and 150 mg are currently ongoing (ClinicalTrials.gov identifiers NCT02308163 and NCT02305849). In conclusion, orally administered oncedaily peficitinib without concomitant use of MTX reduced the symptoms of RA, and a dose-dependent response was observed in the ACR20 and ACR50 response rates as well as in the change from baseline DAS28-CRP.
